BioPharma Resources

Drugs by condition

Drugs approved for hepatitis c

Brand-name prescription drugs and biologics whose FDA label lists hepatitis c as an approved use. Matched on the label phrases: "hepatitis C".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

13

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

7

New molecular entities and new biologics

In development

3

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for hepatitis c.

  • Alvaiz (Eltrombopag Choline) · Teva Pharms INC Nov 29, 2023
  • Epclusa (Sofosbuvir, Velpatasvir) · Gilead Sciences INC Priority reviewOrphanJun 10, 2021
  • Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2021
  • Harvoni (Ledipasvir, Sofosbuvir) · Gilead Sciences INC Priority reviewOrphanAug 28, 2019
  • Sovaldi (Sofosbuvir) · Gilead Sciences INC Priority reviewOrphanAug 28, 2019

All approved drugs for hepatitis c, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 15 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Hepatitis C Virus NS5A Inhibitor (6)

  • Mavyret Glecaprevir, Pibrentasvir · Abbvie · 2017
  • Epclusa Sofosbuvir, Velpatasvir · Gilead Sciences INC · 2016
  • Harvoni Ledipasvir, Sofosbuvir · Gilead Sciences INC · 2014
  • Epclusa Sofosbuvir, Velpatasvir · Gilead Sciences INC · 2021
  • Mavyret Glecaprevir, Pibrentasvir · Abbvie · 2021
  • Harvoni Ledipasvir, Sofosbuvir · Gilead Sciences INC · 2019

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor (3)

  • Vosevi Sofosbuvir, Velpatasvir, Voxilaprevir · Gilead Sciences INC · 2017
  • Sovaldi Sofosbuvir · Gilead Sciences INC · 2013
  • Sovaldi Sofosbuvir · Gilead Sciences INC · 2019

Interferon alpha (1)

  • Pegasys Peginterferon Alfa-2a · Pharmaand Gmbh · 2002

Class not listed in FDA's data (3)

  • Promacta Eltrombopag Olamine · Novartis · 2008
  • Alvaiz Eltrombopag Choline · Teva Pharms INC · 2023
  • Promacta Kit Eltrombopag Olamine · Novartis · 2015

Drugs in development for hepatitis c

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • Bemnifosbuvir-RuzasvirBEM, RZRPhase 32 trials

    Atea Pharmaceuticals, Inc. · HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection

  • BemnifosbuvirAT-527Phase 21 trial

    Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C

  • RuzasvirAT-038Phase 21 trial

    Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C

1 discontinued brand-name drugs whose label still names it

More on hepatitis c: recruiting trials · published research

Related in infectious disease and vaccines: HIV · Hepatitis B · COVID-19 · Influenza · RSV · Urinary tract infection · Pneumonia · Skin infections · C. difficile infection · Fungal infections

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.